SCHEMBL20600660

SCHEMBL20600660

Nc1nc(-c2cccc(F)c2)c(-c2cc(Cl)nc(Cl)c2)n2ccnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 4/20 0.46
ADORA2A P29274 6/20 0.46
ADORA1 P30542 3/20 0.46
CSNK1E P49674 3/20 0.40
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
CDK5 Q00535 2/20 0.40
CDK5R1 Q15078 2/20 0.40
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
HASPIN Q8TF76 1/20 0.40
DPP4 P27487 2/20 0.39
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
ADORA2B P29275 1/20 0.38
IGF1R P08069 1/20 0.37
CACNG2 Q9Y698 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600588 0.92 ADORA2A (0.57) GRIA1ADORA2AADORA1ADORA2B
SCHEMBL20600690 0.91 GRIA1 (0.45) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600459 0.90 GRIA1 (0.46) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600629 0.88 GRIA1 (0.48) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600583 0.86 ADORA2A (0.53) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600734 0.86 GRIA1 (0.43) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600476 0.86 GRIA1 (0.50) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600488 0.85 GRIA1 (0.50) GRIA1ADORA2AADORA1CSNK1ECCNA2
SCHEMBL20600579 0.84 GRIA1 (0.64) GRIA1CSNK1ECCNA2CDK2CDK5
SCHEMBL20600449 0.83 GRIA1 (0.48) GRIA1ADORA2AADORA1CSNK1ECCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 GRIA1 475/4885ADORA2A 1/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.